BioNTech Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

BioNTech heeft een totaal eigen vermogen van €19.1B en een totale schuld van €0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk €22.4B en €3.3B.

Belangrijke informatie

Verhouding schuld/eigen vermogen

€0

Schuld

Rente dekkingsratio	n/a
Contant	€16.71b
Aandelen	€19.11b
Totaal verplichtingen	€3.29b
Totaal activa	€22.40b

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( €18.5B ) 22UA } overtreffen de korte termijn passiva ( €2.5B ).

Langlopende schulden: De kortetermijnactiva 22UA ( €18.5B ) overtreffen de langetermijnschulden ( €764.2M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 22UA is schuldenvrij.

Schuld verminderen: 22UA heeft geen schulden vergeleken met 5 jaar geleden, toen de schuld/eigen vermogen-ratio 3.3% was.

Schuldendekking: 22UA heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.

Rentedekking: 22UA heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.

BioNTech Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million.

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million.

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: EPS: €0.82 (vs €0.67 in 3Q 2023)

BioNTech SE to Report Q3, 2024 Results on Nov 04, 2024

BioNTech and OncoC4 Announce U.S. Food and Drug Administration Placed A Partial Clinical Hold on the Two-Stage, Open-Label, Randomized Phase 3 Trial, PRESERVE-003 (NCT05671510)

Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron KP.2-Adapted Covid-19 Vaccine in the European Union

New major risk - Revenue and earnings growth

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval & Authorization for Omicron KP.2-Adapted COVID-19 Vaccine

Pfizer and BioNTech Provide Update on mRNA -Based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

University of Pennsylvania Files A Lawsuit Against BioNTech SE and Biontech Rna Pharmaceuticals GmbH

Second quarter 2024 earnings released: €3.36 loss per share (vs €0.79 loss in 2Q 2023)

BioNTech SE Reiterates Earnings Guidance for the Year 2024

BioNTech SE to Report Q2, 2024 Results on Aug 05, 2024

New minor risk - Earnings quality

New major risk - Revenue and earnings growth

BioNTech SE Reiterates Revenue Guidance for the Full Year 2024

First quarter 2024 earnings released: €1.31 loss per share (vs €2.07 profit in 1Q 2023)

BioNTech SE to Report Q1, 2024 Results on May 06, 2024

Now 20% undervalued after recent price drop

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: €3.87 (vs €38.78 in FY 2022)

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Receives FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325 DB-1305

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Initiate Pivotal Phase 3 Trial of Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Metastatic Breast Cancer

Robbins LLP Informs Investors of Class Action Filed Against BioNTech SE

BioNTech and Duality Biologics (Suzhou) Co. Ltd. Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Endometrial Cancer

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Aexerna Therapeutics.

BioNTech SE to Report Q4, 2023 Results on Mar 20, 2024

Third quarter 2023 earnings released: EPS: €0.67 (vs €7.43 in 3Q 2022)

Pfizer Inc. and BioNTech SE Announce Positive Topline Data for MRNA-Based Combination Vaccine Program Against Influenza and Covid-19

BioNTech SE, Annual General Meeting, May 17, 2024

BioNTech SE, Annual General Meeting, May 17, 2024

BioNTech SE Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-Based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

Investor sentiment deteriorates as stock falls 15%

New minor risk - Share price stability

Curevac Reports Progress in Intellectual Property Infringement Case Against Biontech in Germany

Pfizer and Biontech Receive Health Canada Authorization for Xbb.1.5-Adapted Monovalent Covid-19 Vaccine

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven